Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TScan Therapeutics, Inc. - Common Stock (NQ:TCRX)

0.3147 -0.0032 (-1.01%)
Streaming Delayed Price Updated: 9:49 AM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 117,979
Open 0.3242
Bid (Size) 0.3124 (100)
Ask (Size) 0.3146 (200)
Prev. Close 0.3179
Today's Range 0.3136 - 0.3242
52wk Range 0.3100 - 2.570
Shares Outstanding 23,976,942
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unusual volume stocks in Tuesday's session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill

Performance

YTD
-69.1%
-69.1%
1 Month
-59.5%
-59.5%
3 Month
-65.9%
-65.9%
6 Month
-72.2%
-72.2%
1 Year
-82.9%
-82.9%

More News

Read More
Here are the top movers in Wednesday's session. ↗
Via Chartmill
Which stocks are gapping on Wednesday? ↗
Via Chartmill
News headline image
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
From Cellares
Via Business Wire
News headline image
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
Via Chartmill
News headline image
Discover the top movers in Monday's pre-market session. ↗
Via Chartmill

Frequently Asked Questions

Is TScan Therapeutics, Inc. - Common Stock publicly traded?
Yes, TScan Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does TScan Therapeutics, Inc. - Common Stock trade on?
TScan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for TScan Therapeutics, Inc. - Common Stock?
The ticker symbol for TScan Therapeutics, Inc. - Common Stock is TCRX on the Nasdaq Stock Market
What is the current price of TScan Therapeutics, Inc. - Common Stock?
The current price of TScan Therapeutics, Inc. - Common Stock is 0.3147
When was TScan Therapeutics, Inc. - Common Stock last traded?
The last trade of TScan Therapeutics, Inc. - Common Stock was at 09/11/26 09:49 AM ET
What is the market capitalization of TScan Therapeutics, Inc. - Common Stock?
The market capitalization of TScan Therapeutics, Inc. - Common Stock is 7.55M
How many shares of TScan Therapeutics, Inc. - Common Stock are outstanding?
TScan Therapeutics, Inc. - Common Stock has 8M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.